Actively Recruiting
A Randomized, Placebo-Controlled Study of Oral Deuruxolitinib to Evaluate Safety and Effectiveness in Japanese Adults With Severe Alopecia Areata, Including an Open-Label Extension
Led by Sun Pharma Japan Limited · Updated on 2026-10-30
78
Participants Needed
18
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of deuruxolitinib in Japanese adults aged 18 to 65 who have severe alopecia areata with at least 50% scalp hair loss. This Phase 3 study includes a double-blind, randomized, placebo-controlled treatment period followed by an open-label extension. The trial aims to assess how well deuruxolitinib works and its safety in this population. Participants will be randomly assigned to receive either deuruxolitinib 8 mg orally twice daily or a matching placebo during the initial 24-week double-blind treatment phase. Following this, all participants will enter a 52-week open-label extension where they will receive deuruxolitinib 8 mg twice daily. This design allows comparison between the drug and placebo initially, then all participants receive the active drug. Throughout the study, participants will undergo regular assessments including measuring scalp hair loss using the Severity of Alopecia Tool SALT score at various weeks. Patient satisfaction and clinician-reported outcomes will also be evaluated. Safety monitoring will include tests for infections and organ function. The primary outcome is the percentage of subjects achieving a SALT score of 20 or less at Week 24. Overall participation lasts up to 76 weeks including both treatment periods.
CONDITIONS
Brief Title
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here